BENITIONSClinical Trial Intelligence

LiveSMART Trial to Prevent Falls in Patients With Cirrhosis

3期 已完成 NCT05794555

适应症Cirrhosis, Liver, Portal Hypertension
分期3期
申办方University of Michigan
状态已完成
受试者人数233 人
干预(药物)Enhanced Usual Care, Lactulose, Investigator recommended exercise, TeleTai-Chi (virtual)
开始日期2023年6月13日
完成日期2025年3月7日
结果公布日2026年7月31日

摘要

This multicenter trial is being conducted to determine if sequential lactulose and Tele (virtual) Tai-Chi reduces the rate of injurious fall, non-injurious falls, incident overt Hepatic Encephalopathy (HE), and death or liver transplant over 24 weeks. Participants that are enrolled will be randomized to stage one of this project for approximately 12 weeks. After completing stage one, participants will be re-randomized to stage 2 of the project that will last approximately 12 more weeks. The study hypothesizes that sequential lactulose/TeleTai-Chi will reduce falls, incident overt HE, death and physical frailty and will improve cognitive function, and Health Related Quality of Life (HRQOL) over 24 weeks compared to other treatment combinations. As detailed below, an observational component that enrolls caregivers of the trial participants is being conducted. Upon completion, Participants listed in the record here only include trial participants; and the observational component was moved to a new registration for clarity, NCT07140120.

Number of Participants Experiencing a Hierarchical Composite of Events Over 24 Weeks: Injurious Falls, Non-injurious Falls, Incident Hepatic Encephalopathy, Liver Transplant, and Death/Transplant

Baseline to 24 weeks · Participants

Treatment (Lactulose) Plus Enhanced Usual Care Then TeleTai-Chi Exercise Classes11 Participants
Treatment (Lactulose) Plus Enhanced Usual Care Then Recommended Exercise10 Participants
Enhanced Usual Care Group Followed by Tele-Tai Chi Exercise Classes14 Participants
Enhanced Usual Care Group Followed by Investigator Recommended Exercise29 Participants
p-value0.003

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

全部试验

本页整理自 ClinicalTrials.gov 的公开数据,不构成医疗建议,也不构成投资建议。请务必咨询专业医师。